Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) has paused enrollment in clinical trials with BCX9930 as the Company investigates elevated serum creatinine levels seen in some patients. The Company will not enroll new patients in the REDEEM-1, REDEEM-2, or RENEW clinical trials during the investigation. Patients currently enrolled in the trials are continuing on the study…
Benzinga ·
The Guardian - UK
Euronews
The Economic Times
The Independent UK
Benzinga
Fortune
The Conversation
The Guardian - AU
AAP
International Business Times
Al Jazeera
France 24
